|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||92.56 / 141.86|
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
The Dow posts a record close with the S&P 500 lower, while tech stocks dragged on the Nasdaq as Wall Street looks to a Fed decision on interest rates Tuesday.
The Dow rises but pares gains as Wall Street looks to a Fed decision on interest rates later in the week.
For health care investors, CEO vacancies at two of the six big-cap biotech companies aren't helping sentiment heading into 2017.
Here's a technical look on how to trade some of the most active stocks on the market this week.
Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Alexion Pharmaceuticals, Inc.
Stocks are mixed Monday as oil prices surge after non-OPEC countries agree to cut production and markets anticipate Fed moves.
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
Alexion Pharmaceuticals fired its CEO and chief financial officer Monday amidst an internal probe into allegations of improper sales practices tied to its top-selling drug Soliris.
The Board of Directors of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that it has named David Brennan as Interim Chief Executive Officer, effective immediately.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that new data from an ongoing Phase 1/2 dose-escalation study of ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH) showed rapid and sustained...
The Nasdaq rose 0.7% to an all-time high of 5,403. The S&P 500 was up 0.3%, and the Dow Jones Industrial Average gained 0.2%.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the Citi 2016 Global Healthcare Conference on Wednesday, December 7, 2016 at 11:00 a.
Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new data from an analysis of patients enrolled in the Global atypical Hemolytic Uremic Syndrome (aHUS) Registry, demonstrating that...
Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it received a notification letter on November 15, 2016 from The NASDAQ Stock Market ("NASDAQ").
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that researchers presented new longer-term data from an ongoing, open-label extension of the pivotal Phase 3 ARISE trial of Kanuma ® (sebelipase alfa) in...
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Alexion Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals disclosed Wednesday its board of directors is investigating allegations of improper sales practices tied to its top-selling drug Soliris.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has filed with the U.
The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.
Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present new interim data from a Phase 1/2 dose-escalation study of ALXN1210, the Company's investigational, highly innovative longer-acting...
Here's a window into what institutional investors may be doing and how to profit from that.
Consider buying this biotech stock on weakness after a strong run higher Thursday.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.